Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Down 51.4% in April

Key Points

• Short interest fell 51.4% in April to 236,711 shares, representing 0.9% of the stock and a short-interest ratio of 1.4 days.
• Rein reported a Q1 EPS loss of ($0.36) versus an expected ($0.24) and analysts project a full-year EPS of -1.63; the stock trades around $1.66 with a market cap of about $46.6 million.
• Institutional ownership is high at 90.89% with several firms initiating small stakes recently, while analyst coverage is mixed and the consensus rating is a "Hold" with a $8 target.

Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 236,711 shares, a decrease of 51.4% from the March 31st total of 487,162 shares. Currently, 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 168,475 shares, the short-interest ratio is presently 1.4 days.

Institutional Trading of Rein Therapeutics

Institutional investors have recently made changes to their positions in the company. Gleason Group Inc. purchased a new stake in shares of Rein Therapeutics during the 3rd quarter valued at approximately $26,000. Susquehanna International Group LLP purchased a new stake in shares of Rein Therapeutics during the 3rd quarter valued at approximately $35,000. HRT Financial LP purchased a new stake in shares of Rein Therapeutics during the 4th quarter valued at approximately $38,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Rein Therapeutics during the 2nd quarter valued at approximately $68,000. Finally, Jane Street Group LLC purchased a new stake in shares of Rein Therapeutics during the 4th quarter valued at approximately $72,000. Hedge funds and other institutional investors own 90.89% of the company's stock.

Rein Therapeutics Price Performance

Rein Therapeutics stock opened at $1.66 on Friday. The firm has a 50 day simple moving average of $1.36 and a 200-day simple moving average of $1.35. The stock has a market cap of $46.55 million, a price-to-earnings ratio of -0.85 and a beta of 1.40. Rein Therapeutics has a 1-year low of $1.02 and a 1-year high of $2.40.

Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.12). Equities analysts expect that Rein Therapeutics will post -1.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RNTX has been the subject of a number of recent research reports. cut shares of Rein Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, January 21st. Citigroup cut shares of Rein Therapeutics to a "hold" rating in a research report on Wednesday, January 21st. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $8.00.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.